Phase I study of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer

Japanese Journal of Clinical Oncology

Volumn 37, Issue 5, 2007, Pages 353-357

  Takatani, Hiroshi ^a   Soda, Hiroshi ^b   Nakamura, Yoichi ^b   Kinoshita, Akitoshi ^c   Fukuda, Masaaki ^d   Nagashima, Seiji ^e   Fukuda, Minoru ^f   Soejima, Yoshifumi ^g   Nakano, Hirofumi ^b   Oka, Mikio ^f   Kohno, Shigeru ^b  

^a Nagasaki Municipal Hospital   (Japan)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^d Japanese Red Cross Nagasaki Atomic Bomb Hospital Nagasaki   (Japan)

^e Sasebo General Hospital   (Japan)

^f KAWASAKI MEDICAL SCHOOL   (Japan)

^g Ureshino Medical Center   (Japan)

Author keywords

Hypopharyngeal cancer; Overall treatment time; Radiotherapy

Indexed keywords

GEMCITABINE; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; JAPAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; TREATMENT OUTCOME;

EID: 34547924503     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym030     Document Type: Article

References (19)

1. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using update data on individual patients from 52 randomized clinical trials. Br Med J 1995;311:899-909.
2. Bunn PA, Jr., Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions. Clin Cancer Res 1998;4:1087-100.
3. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimator M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004;22:3852-9.
4. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S, Jr, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 2004;22:330-53.
5. Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH. High dose cis-platinum diammine dichloride: Amelioration of renal toxicity by mannitol diuresis. Cancer 1977;39:1372-81.
6. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004;22:3852-9.
7. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, et al. Antitumor activity of 7-ethyl-10-(4-(1-piperidino)-1-piperidino) carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987;47:5944-7.
8. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991;51:4187-91.
9. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992;10:16-20.
10. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995;22:3-10.
11. Kaye SB. Gemcitabine: Current status of phase I and II trials. J Clin Oncol 1994;12:1527-31.
12. Bahadori HR, Rocha Lima CMS, Green MR, Safa AR. Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines. Anticancer Res 1999;19:5423-8.
13. Kakolyris SS, Kouroussis C, Koukourakis M, Kalbakis K, Mavroudis D, Vardakis N, et al. A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy. Anticancer Res 2002;22:1891-6.
14. Pectasides D, Mylonakis N, Farmakis D, Nikolaou M, Koumpou M, Katselis I, et al. Irinotecan and gemcitabine in patients with advanced non-small cell lung cancer, previously treated with cisplatin-based chemotherapy. A phase II study. Anticancer Res 2003;23:4205-11.
15. National Cancer Institute. Common Toxicity Criteria, ver. 2. Bethesda: National Cancer Institute 1999.
16. Therasse P, Arbuck S, Eisenhauer E. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
17. Nishio M, Ohyanagi F, Taguch F, Matsuda M, Sato Y, Okumura S, et al. Phase I study of combination chemotherapy with gemcitabine and irinotecan for non-small cell lung cancer. Lung Cancer 2005;48:115-9.
18. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007;18:317-23.
19. Ramnath N, Khushalani N, Toth K, Litwin AM, Intengan ME, Slocum HK, et al. S-phase modulation by irinotecan: Pilot studies in advanced solid tumors. Cancer Chemother Pharmacol 2005;56:447-54.